ASX - By Stock
|
DXB |
Re:
New NDF Report: DXB
|
|
Ahmed
|
5 |
1.4K |
2 |
19/10/16 |
19/10/16 |
ASX - By Stock
|
5
|
1.4K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
|
|
Ahmed
|
220 |
38K |
0 |
18/10/16 |
18/10/16 |
ASX - By Stock
|
220
|
38K
|
0
|
|
ASX - By Stock
|
DXB |
New NDF Report: DXB
|
|
Ahmed
|
5 |
1.4K |
9 |
18/10/16 |
18/10/16 |
ASX - By Stock
|
5
|
1.4K
|
9
|
|
ASX - By Stock
|
4DS |
Re:
Interesting
|
|
Ahmed
|
8 |
3.7K |
1 |
15/10/16 |
15/10/16 |
ASX - By Stock
|
8
|
3.7K
|
1
|
|
ASX - By Stock
|
MNQ |
Re:
Information on re-listing
|
|
Ahmed
|
80 |
32K |
2 |
12/10/16 |
12/10/16 |
ASX - By Stock
|
80
|
32K
|
2
|
|
ASX - By Stock
|
DXB |
*New* Bioshares Research Note
|
|
Ahmed
|
3 |
820 |
4 |
11/10/16 |
11/10/16 |
ASX - By Stock
|
3
|
820
|
4
|
|
ASX - By Stock
|
DXB |
The Next Biotech Article
|
|
Ahmed
|
3 |
1.3K |
10 |
10/10/16 |
10/10/16 |
ASX - By Stock
|
3
|
1.3K
|
10
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
|
|
Ahmed
|
220 |
38K |
12 |
07/10/16 |
07/10/16 |
ASX - By Stock
|
220
|
38K
|
12
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
|
|
Ahmed
|
220 |
38K |
1 |
07/10/16 |
07/10/16 |
ASX - By Stock
|
220
|
38K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
|
|
Ahmed
|
220 |
38K |
0 |
06/10/16 |
06/10/16 |
ASX - By Stock
|
220
|
38K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
|
|
Ahmed
|
220 |
38K |
0 |
06/10/16 |
06/10/16 |
ASX - By Stock
|
220
|
38K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
|
|
Ahmed
|
220 |
38K |
0 |
06/10/16 |
06/10/16 |
ASX - By Stock
|
220
|
38K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
|
|
Ahmed
|
220 |
38K |
2 |
06/10/16 |
06/10/16 |
ASX - By Stock
|
220
|
38K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
|
|
Ahmed
|
220 |
38K |
6 |
05/10/16 |
05/10/16 |
ASX - By Stock
|
220
|
38K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
|
|
Ahmed
|
220 |
38K |
0 |
04/10/16 |
04/10/16 |
ASX - By Stock
|
220
|
38K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
|
|
Ahmed
|
220 |
38K |
3 |
04/10/16 |
04/10/16 |
ASX - By Stock
|
220
|
38K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
|
|
Ahmed
|
220 |
38K |
11 |
04/10/16 |
04/10/16 |
ASX - By Stock
|
220
|
38K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
This page sums up Dimerix's opportunities
|
|
Ahmed
|
9 |
2.9K |
1 |
22/09/16 |
22/09/16 |
ASX - By Stock
|
9
|
2.9K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Annual Report to shareholders-DXB.AX
|
|
Ahmed
|
17 |
4.5K |
5 |
21/09/16 |
21/09/16 |
ASX - By Stock
|
17
|
4.5K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Annual Report to shareholders-DXB.AX
|
|
Ahmed
|
17 |
4.5K |
4 |
20/09/16 |
20/09/16 |
ASX - By Stock
|
17
|
4.5K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Annual Report to shareholders-DXB.AX
|
|
Ahmed
|
17 |
4.5K |
1 |
20/09/16 |
20/09/16 |
ASX - By Stock
|
17
|
4.5K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
TA perspective
|
|
Ahmed
|
49 |
15K |
2 |
20/09/16 |
20/09/16 |
ASX - By Stock
|
49
|
15K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Companies listed in Glomerulonephritis - Pipeline Review and their valuations.
|
|
Ahmed
|
63 |
14K |
8 |
15/09/16 |
15/09/16 |
ASX - By Stock
|
63
|
14K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Companies listed in Glomerulonephritis - Pipeline Review and their valuations.
|
|
Ahmed
|
63 |
14K |
14 |
15/09/16 |
15/09/16 |
ASX - By Stock
|
63
|
14K
|
14
|
|
IPOs
|
|
Re:
HearMeOut IPO
|
|
Ahmed
|
3 |
1.4K |
1 |
13/09/16 |
13/09/16 |
IPOs
|
3
|
1.4K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Market Cap
|
|
Ahmed
|
35 |
7.5K |
1 |
13/09/16 |
13/09/16 |
ASX - By Stock
|
35
|
7.5K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Market Cap
|
|
Ahmed
|
35 |
7.5K |
0 |
13/09/16 |
13/09/16 |
ASX - By Stock
|
35
|
7.5K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Market Cap
|
|
Ahmed
|
35 |
7.5K |
4 |
13/09/16 |
13/09/16 |
ASX - By Stock
|
35
|
7.5K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix vs Retrophin
|
|
Ahmed
|
40 |
12K |
1 |
13/09/16 |
13/09/16 |
ASX - By Stock
|
40
|
12K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix vs Retrophin
|
|
Ahmed
|
40 |
12K |
2 |
12/09/16 |
12/09/16 |
ASX - By Stock
|
40
|
12K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix vs Amyndas
|
|
Ahmed
|
1 |
566 |
3 |
11/09/16 |
11/09/16 |
ASX - By Stock
|
1
|
566
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix vs Retrophin
|
|
Ahmed
|
40 |
12K |
0 |
11/09/16 |
11/09/16 |
ASX - By Stock
|
40
|
12K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix vs Retrophin
|
|
Ahmed
|
40 |
12K |
4 |
11/09/16 |
11/09/16 |
ASX - By Stock
|
40
|
12K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix vs Retrophin
|
|
Ahmed
|
40 |
12K |
5 |
11/09/16 |
11/09/16 |
ASX - By Stock
|
40
|
12K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
DXB : Daily Trading Volume Spike
|
|
Ahmed
|
16 |
3.3K |
4 |
10/09/16 |
10/09/16 |
ASX - By Stock
|
16
|
3.3K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix vs Retrophin
|
|
Ahmed
|
40 |
12K |
3 |
09/09/16 |
09/09/16 |
ASX - By Stock
|
40
|
12K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Example Of GPCR Deals In This Space and don't shout in the title please.
|
|
Ahmed
|
15 |
2.6K |
0 |
07/09/16 |
07/09/16 |
ASX - By Stock
|
15
|
2.6K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: NDF initiates coverage of Dimerix-DXB.AX
|
|
Ahmed
|
32 |
5.2K |
0 |
26/08/16 |
26/08/16 |
ASX - By Stock
|
32
|
5.2K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: NDF initiates coverage of Dimerix-DXB.AX
|
|
Ahmed
|
32 |
5.2K |
0 |
26/08/16 |
26/08/16 |
ASX - By Stock
|
32
|
5.2K
|
0
|
|
ASX - By Stock
|
TRS |
Re:
Ann: Media Release Full Year Results-TRS.AX
|
|
Ahmed
|
53 |
11K |
0 |
24/08/16 |
24/08/16 |
ASX - By Stock
|
53
|
11K
|
0
|
|
ASX - By Stock
|
MVL |
Re:
Personal Brief Analysis
|
|
Ahmed
|
2 |
925 |
1 |
15/08/16 |
15/08/16 |
ASX - By Stock
|
2
|
925
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Outcomes of DMX-200 pre-IND meeting with the FDA-DXB.AX
|
|
Ahmed
|
90 |
14K |
5 |
15/08/16 |
15/08/16 |
ASX - By Stock
|
90
|
14K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Outcomes of DMX-200 pre-IND meeting with the FDA-DXB.AX
|
|
Ahmed
|
90 |
14K |
2 |
13/08/16 |
13/08/16 |
ASX - By Stock
|
90
|
14K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Outcomes of DMX-200 pre-IND meeting with the FDA-DXB.AX
|
|
Ahmed
|
90 |
14K |
0 |
10/08/16 |
10/08/16 |
ASX - By Stock
|
90
|
14K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Outcomes of DMX-200 pre-IND meeting with the FDA-DXB.AX
|
|
Ahmed
|
90 |
14K |
0 |
09/08/16 |
09/08/16 |
ASX - By Stock
|
90
|
14K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Outcomes of DMX-200 pre-IND meeting with the FDA-DXB.AX
|
|
Ahmed
|
90 |
14K |
4 |
08/08/16 |
08/08/16 |
ASX - By Stock
|
90
|
14K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Outcomes of DMX-200 pre-IND meeting with the FDA-DXB.AX
|
|
Ahmed
|
90 |
14K |
1 |
07/08/16 |
07/08/16 |
ASX - By Stock
|
90
|
14K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Outcomes of DMX-200 pre-IND meeting with the FDA-DXB.AX
|
|
Ahmed
|
90 |
14K |
3 |
06/08/16 |
06/08/16 |
ASX - By Stock
|
90
|
14K
|
3
|
|
ASX - By Stock
|
DXB |
DXB- Under the Radar, Undervalued...
|
|
Ahmed
|
0 |
419 |
8 |
06/08/16 |
06/08/16 |
ASX - By Stock
|
0
|
419
|
8
|
|
ASX - By Stock
|
SFI |
Re:
Ann: Spookfish Partners with EagleView in North America-SFI.AX
|
|
Ahmed
|
34 |
14K |
4 |
17/05/16 |
17/05/16 |
ASX - By Stock
|
34
|
14K
|
4
|
|